Abstract
In the last decade, several oral agents have become available for treating patients with pulmonary arterial hypertension (PAH). The newest such agent is selexipag (Uptravi; FDA-approved December 21, 2015), an oral selective intrapulmonary prostacyclin-receptor agonist. Selexipag potentially could delay initiation of therapy with intravenous (IV) prostacyclin. In this …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.